TRANSTHERA-B (02617) has announced the fulfillment of all conditions under the placement agreement, with the placement completed on April 21, 2026. The placing agent successfully allocated a total of 5.085 million placement shares to no fewer than six placees at a price of HK$57.03 per share. These shares represent approximately 1.67% of the existing issued H-shares and 1.27% of the total issued shares prior to completion. Following the issuance, they account for about 1.65% of the enlarged H-share capital and 1.26% of the total issued shares. Gross proceeds from the placement amounted to roughly HK$290 million, with net proceeds, after deducting commissions and related expenses, totaling approximately HK$282 million. The net issue price per share is calculated at HK$55.49. The company plans to allocate the net proceeds as follows: approximately 57% will be directed toward research and development, including clinical development of the core product Tinengotinib for indications such as advanced breast cancer, hepatocellular carcinoma, and castration-resistant prostate cancer, as well as clinical development of TT-00973; about 33% will be used for the production and commercialization of Tinengotinib in China, encompassing the establishment of a commercial team and related marketing activities; and the remaining 10% will be allocated for working capital and general corporate purposes.